In a world where medical solutions are constantly evolving, OLIGOFASTX emerges as a beacon of hope for those battling rare diseases with no existing treatments. This groundbreaking project spearheaded by our CDMO aims to revolutionize therapy development, paving the way for novel oligonucleotide-based treatments like antimiRNAs, siRNAs, and aptamers.
With OLIGOFASTX, we’re not just creating therapies – we’re shaping a future where patients have access to life-changing treatments that were once deemed impossible.
OLIGOFASTX: A COMPREHENSIVE PLATFORM FOR THE SUSTAINABLE DEVELOPMENT OF OLIGONUCLEOTIDE-BASED THERAPEUTICS
Dossier no: EXP – 00145734 / MIG-20211028
Main objective of the project: To develop an integral platform for new therapies based on oligonucleotides (AntimiRNAs, siRNAs and aptamers) that promotes and facilitates the arrival on the market of new therapies for the treatment of rare diseases with no medical response.
Deadline: From 01/10/2021 to 31/12/2024.
Project funded by the European Union – Next Generation EU within the Recovery, Transformation and Resilience Plan. Subsidised by the CDTI.
Grant awarded: 375,856.00 €.
OLIGOFASTX: PLATAFORMA INTEGRAL PARA EL DESARROLLO SOSTENIBLE DE TERAPIAS BASADAS EN OLIGONUCLEÓTIDOS
Nº expediente: EXP – 00145734 / MIG-20211028
Objetivo principal del proyecto: Desarrollar una plataforma integral para nuevas terapias basadas en oligonucleótidos (AntimiRNAs, siRNAs y aptámeros) que impulse y facilite la llegada al mercado de nuevas terapias para el tratamiento de enfermedades raras sin respuesta médica.
Plazo de realización: Desde el 01/10/2021 al 31/12/2024
Proyecto financiado por la Unión Europea – Next Generation EU dentro del Plan de Recuperación, Transformación y Resiliencia. Subvencionado por el CDTI.
Subvención concedida: 375.856,00 €
About 53Biologics:
53Biologics is a CDMO with specialized in biologics production, from pDNA to proteins. In order to serve as leaders in biologics development and manufacturing, our mission is to support you whenever you need us, starting in preclinical development up to commercialization.
For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pdelamadrid@53biologics.com